Skip to main content
Top

Familial Cancer

Issue 1/2004

Content (13 Articles)

Cancer variation associated with the position of the mutation in the BRCA2 gene

Jan Lubinski, Catherine M. Phelan, Parviz Ghadirian, Henry T. Lynch, Judy Garber, Barbara Weber, Nadine Tung, Douglas Horsman, Claudine Isaacs, Alvaro N. A. Monteiro, Ping Sun, Steven A. Narod

The 1100delAT BRCA1 and the 8765delAG BRCA2 Mutations: Occurrence in High-Risk Non-Ashkenazi Jews and Haplotype Comparison of Jewish and Non-Jewish Carriers

Inbar Gal, Ruth Gershoni Baruch, Daniel Haber, Efrat Dagan, Shlomit Eisenberg-Barzilai, Jamal Zidan, Eitan Friedman

BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect

Danièle Muller, Catherine Bonaiti-Pelié, Joseph Abecassis, Dominique Stoppa-Lyonnet, Jean-Pierre Fricker

Intron 4 Mutation in APC Gene Results in Splice Defect and Attenuated FAP Phenotype

Deborah W. Neklason, Cindy H. Solomon, Amy L. Dalton, Scott K. Kuwada, Randall W. Burt

Frequency of extra-colonic tumors in hereditary nonpolyposis colorectal cancer (HNPCC) and familial colorectal cancer (FCC) Brazilian families: An analysis by a Brazilian Hereditary Colorectal Cancer Institutional Registry

Fáblio Oliveira Ferreira, Claudia Cristina Napoli Ferreira, Benedito Mauro Rossi, Wilson Toshihiko Nakagawa, Samuel Aguilar Jr., Erika Maria Monteiro Santos, Marcelo Leite Vierira Costa, Ademar Lopes

Familial Pancreatic Cancer

Harald Rieder, Detlef K. Bartsch

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine